CE2023-12-01T11:13:05
Under its proposed acquisition of ImmunoGen, AbbVie will gain rights to ELAHERE®, the first antibody-drug conjugate (ADC) approved in ovarian cancer.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-10-27T10:14:00Z
Sponsored by Capsugel
2026-10-22T10:54:00Z
2026-10-21T11:35:00Z
2026-10-19T13:13:00Z
2026-06-29T06:00:00
Sponsored by Lubrizol Advanced Materials Europe BV
2026-07-13T07:00:00
Sponsored by Thermo Fisher Scientific
2026-03-27T15:37:00
Sponsored by IMA Pharma
2026-04-30T10:37:00
Sponsored by Shimadzu
2026-06-22T13:25:00
Sponsored by IMA Pharma
2026-08-27T14:30:00
Sponsored by Waters Corporation
Site powered by Webvision Cloud